Lupus & antiphospholipid syndrome
Scoping Review of Human Longitudinal Studies of Biomarkers Associated with Risk of Developing Systemic Lupus Erythematosus (SLE) to Inform the Development of a Novel SLE Risk Stratification Index
Authors' conclusion
his review maps the breadth of candidate biomarkers associated with the risk of developing SLE and the heterogeneity of the evidence supporting them. Building a clinically useful SLE risk-stratification index will need a shared definition of the at-risk state, and prospective studies that follow biomarkers over time, in populations from broader geographical regions.
Study context
- Population
- Longitudinal human studies in which biomarkers were measured before an incident diagnosis or classification of SLE59 original studies and two meta-analyses included
- Outcome
- Included studies
Methodological detailsPRISMA-ScR, three databases searched, Population, Exposure, Comparator, Outcome framework
- PRISMA-ScR
- Three databases searched
- Population, Exposure, Comparator, Outcome framework
Main finding
As reported in the abstract
- Original studies included
- 59
- Meta-analyses included
- two
Further findings
- Most evidence concerned conventional serological markers; interferon and cytokine signatures, proteomic panels, and genetic risk scores were examined in fewer, recent cohorts
- Few biomarkers were studied across multiple populations or with comparable follow-up, outcome definitions, and analytic methods; most associations came from single studies without external validation
- Longitudinal biomarker trajectories before onset were rarely characterized, and non-European populations were under-represented
Original publication
Scoping Review of Human Longitudinal Studies of Biomarkers Associated with Risk of Developing Systemic Lupus Erythematosus (SLE) to Inform the Development of a Novel SLE Risk Stratification Index. Arthritis Care Res (Hoboken). Published 11 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →